BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, March 9, 2026
See today's BioWorld
Home
» New Samyang Holdings, Samsung Biologics spin-offs debut on Kospi
To read the full story,
subscribe
or
sign in
.
New Samyang Holdings, Samsung Biologics spin-offs debut on Kospi
Nov. 24, 2025
By
Marian (YoonJee) Chu
No Comments
Two South Korean conglomerates – Samyang Holdings Corp. and Samsung Biologics Co. Ltd. – listed their newly spun-off biopharmaceutical units on Korea Exchange’s (KRX) main trading board Nov. 24.
BioWorld
Deals and M&A
Financings
Cancer
Dermatologic
Antibody-drug conjugate
Biosimilar
Immuno-oncology
Asia-Pacific